文献速递骨软组织肉瘤与黑色素瘤

经皮肝灌注联合伊匹木单抗和纳武利尤单抗治疗转移性葡萄膜黑色素瘤(CHOPIN):单中心、开放标签、随机2期试验

Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2026-01-01

这项单中心随机2期试验纳入76例不可切除的肝转移为主或仅肝转移的转移性葡萄膜黑色素瘤初治患者,随机接受经皮肝灌注单用或联合伊匹木单抗+纳武利尤单抗。

要点

  • 联合组3-4级不良事件发生率达82%,显著高于单用组的41%。
  • 联合组发生1例治疗相关死亡(三重M综合征)。

核心结论

  • 在经皮肝灌注基础上联合伊匹木单抗和纳武利尤单抗显著改善转移性葡萄膜黑色素瘤患者的无进展生存,但不良事件发生率更高。

研究设计与样本

  • 研究者发起的单中心、开放标签、随机2期试验,纳入76例18-80岁不可切除的肝转移为主或仅肝转移、WHO体能状态0-1、未接受过系统治疗的转移性葡萄膜黑色素瘤患者,1:1随机分配至经皮肝灌注单用组(n=38)或联合伊匹木单抗+纳武利尤单抗组(n=38)。

主要发现

  • 联合组3-4级治疗相关不良事件发生于38例中的31例(82%),单用组发生于37例中的15例(41%)。
  • 最常见的3-4级不良事件为血小板减少(联合组13例[34%] vs 单用组5例[14%])、白细胞减少(10例[26%] vs 5例[14%])、γ-谷氨酰转移酶升高(7例[18%] vs 3例[8%])和贫血(5例[13%] vs 1例[3%])。
  • 联合组发生1例治疗相关死亡(三重M综合征)。

关键数值与推荐

  • 经皮肝灌注方案:美法仑3 mg/kg(最大220 mg),第1周和第7周各进行两次灌注。
  • 联合组免疫治疗方案:伊匹木单抗1 mg/kg和纳武利尤单抗3 mg/kg静脉给药,每3周一次,于第0、3、6、9周给药,无维持治疗。
  • 主要终点为意向治疗人群的1年无进展生存率;安全性分析纳入所有接受治疗的患者,采用CTCAE 5.0版前瞻性收集和分级。

临床怎么用

  • 对于不可切除的肝转移为主或仅肝转移的转移性葡萄膜黑色素瘤初治患者,可考虑经皮肝灌注联合伊匹木单抗和纳武利尤单抗以提高无进展生存。
  • 联合方案治疗相关毒性显著增加,需密切监测血小板减少、白细胞减少、肝酶升高和贫血等不良事件。
  • 该联合方案为转移性葡萄膜黑色素瘤提供了一种有前景的新治疗范式,但需在更大规模多中心随机试验中验证。

局限性

  • 单中心、开放标签设计可能引入偏倚。
  • 样本量较小(共76例),结果需在更大规模多中心随机试验中验证。
  • 葡萄膜黑色素瘤发病率低,开展此类研究具有挑战性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Percutaneous hepatic perfusion can lead to meaningful hepatic tumour control in metastatic uveal melanoma, but its benefit is confined to liver metastases and does not address extrahepatic disease. Immune checkpoint inhibitors ipilimumab and nivolumab show limited activity in uveal melanoma, although retrospective studies suggest improved outcomes when combined with liver-directed therapies. This study aimed to evaluate the efficacy and safety of combining percutaneous hepatic perfusion with ipilimumab and nivolumab. METHODS: In this investigator-initiated, single-centre, open-label, randomised, phase 2 trial, adults aged 18-80 years with unresectable liver-only or liver-dominant metastatic uveal melanoma, WHO performance status 0-1, and with no previous systemic therapy were randomly assigned (1:1) to receive percutaneous hepatic perfusion alone (perfusion group) or percutaneous hepatic perfusion combined with ipilimumab plus nivolumab (combination group). Two perfusions with melphalan (3 mg/kg; maximum 220 mg) were scheduled in weeks 1 and 7. The combination group also received intravenous ipilimumab (1 mg/kg) and nivolumab (3 mg/kg) once every 3 weeks in weeks 0, 3, 6, and 9 without maintenance therapy. The primary endpoint, 1-year progression-free survival, was analysed in the intention-to-treat population; the safety analysis included all treated patients and was prospectively collected and graded using Common Terminology Criteria for Adverse Events version 5.0. The trial is registered with ClinicalTrials.gov (NCT04283890) and EudraCT (2018-004248-49) and is ongoing but no longer enrolling. FINDINGS: Between Dec 10, 2020, and Nov 15, 2024, 80 patients were screened, of whom 76 were eligible and assigned to the combination group (n=38) or perfusion group (n=38), including 49 (64%) men and 27 (36%) women. Median follow-up was 24·9 months (IQR 15·4-36·0). 1-year progression-free survival was 54·7% (95% CI 36·8-69·5) with combination therapy versus 15·8% (5·8-30·1) with perfusion alone (adjusted hazard ratio 0·34 [95% CI 0·19-0·60]; p=0·0002). Grade 3-4 treatment-related adverse events occurred in 31 (82%) of 38 patients with combination therapy compared to 15 (41%) of 37 patients with perfusion alone, due to both a higher incidence of severe perfusion-related events and immunotherapy-related adverse events. The most common grade 3-4 adverse events were thrombocytopenia (13 [34%] in the combination group vs five [14%] in the perfusion group), leukopenia (ten [26%] vs five [14%]), γ-glutamyl transferase increase (seven [18%] vs three [8%]), and anaemia (five [13%] vs one [3%]). One treatment-related death (due to triple M syndrome) occurred in the combination group. INTERPRETATION: Adding ipilimumab and nivolumab to percutaneous hepatic perfusion significantly improved progression-free survival, but with a higher rate of adverse events. The combination therapy offers a promising new treatment paradigm for patients with metastatic uveal melanoma. These results would ideally be validated in larger, multicentre randomised trials; however, conducting such studies is challenging due to the low incidence of uveal melanoma. FUNDING: Leiden University Medical Centre, Delcath Systems, and Bristol Myers Squibb.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. van den Hoek L, Burgmans M, Tong T, et al. Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2026. PMID: 41785896. doi:10.1016/S1470-2045(25)00720-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。